{"prompt": "['Table 14', 'Clopper-Pearson 95% Cls for the Incidence of AEs (Based on N=200)', 'Number of AE Events', '(Observed AE Incidence)', '95% Clopper-Pearson Cls', '5 (2.5%)', '0.8%-5.7%', '10 (5.0%)', '2.4%-9.0%', '20 (10.0%)', '6.2%-15.0%', '30 (15.0%)', '10.4%-20.7%', 'AE=adverse event, Cl=confidence interval', '6.2', 'SUMMARIES OF CONDUCT OF STUDY', 'Flow of patients through the study will be displayed in a \"Consolidated Standards of', \"Reporting Trials (CONSORT)' diagram. A clear account of all patients who enrolled in the\", 'study and who entered, discontinued, and completed the initial and maintenance phases of', 'the study will be displayed. The reasons for premature discontinuation from study treatment', 'and the reasons for study withdrawal will be described. In addition, the number of patients', 'who received dose up-titration will also be described. Enrollment and major protocol', 'deviations will be listed and evaluated for their potential effects on the interpretation of study', 'results. Major protocol deviations and the number of patients with at least one major protocol', 'deviation will be summarized in terms of both the safety and ITT populations.', 'Observation time and duration of follow-up will be summarized.', '6.3', 'SUMMARIES OF DEMOGRAPHIC AND BASELINE', 'CHARACTERISTICS', 'Demographic and baseline characteristics (including age, sex, and self-reported race and', 'ethnicity) will be summarized using means, standard deviations, medians, and ranges for', 'continuous variables and frequencies and percentages for categorical variables, as appropriate.', 'For each variable (continuous or categorical), the number of available observations will be', 'reported. Medical history will be tabulated and previous concomitant medications will be', 'summarized.', '6.4', 'SAFETY ANALYSES', 'The primary objective of this study is to evaluate the overall safety and tolerability of', 'prophylactic administration of emicizumab in patients with congenital hemophilia A who have', 'persistent inhibitors against FVIII at enrollment. Of primary interest in this study are the', 'incidence and severity of all adverse events, including thromboembolic events,', 'microangiopathic hemolytic anemia or TMA, systemic hypersensitivity, anaphylaxis, and', 'anaphylactoid events.', 'All adverse events will be assessed according to the WHO toxicity grading scale. The', 'incidence, type, and grade of adverse events will be summarized according to the primary', 'system-organ class (SOC) and, within each SOC, by Medical Dictionary for Regulatory', 'Activities (MedDRA) preferred term. For each adverse event, data will be provided on the', 'timing (start and stop date, time of onset in comparison with last dose of emicizumab', 'received, and doses of emicizumab received), severity, relationship to emicizumab, outcome,', 'Emicizumab - F. Hoffmann-La Roche Ltd', '143 / Protocol MO39129, Version 3']['and effect on therapy. The data may be presented together with two-sided 95% Clopper-', 'Pearson Cls if appropriate.', 'In addition, as part of the safety evaluation, additional assessments will be summarized', 'descriptively as follows:', 'Cumulative study medication doses, dose modifications (delays and interruptions), and', 'duration of exposure', 'Compliance with respect to emicizumab intake (planned VS. received)', 'Changes from baseline in physical examination findings', 'Vital signs over time:', 'Vital signs will be analyzed using descriptive statistics for continuous variables and', 'presented graphically over time with associated 95% Cls.', 'Laboratory parameters (hematology and chemistry):', 'These parameters will be presented in shift tables of WHO toxicity grade at baseline', 'versus worst grade during the treatment period. Selected laboratory parameters will', 'be summarized in terms of mean, standard deviation, minimum, and maximum.', 'Laboratory parameters will also be presented graphically over time, if appropriate.', 'All safety variables will be analyzed for the safety population. For each variable, the number', 'of available observations will be reported. The safety population includes all patients who', 'have received at least one dose of emicizumab.', 'The primary safety analysis will occur at the end of the study.', 'The iDMC (see Section 0) will evaluate the study data, including the emerging safety results,', 'at periodic reviews and recommend to the Sponsor whether the protocol should be amended or', 'the study should be stopped early. All summaries and analyses will be prepared by the Study', 'Management Team (SMT) statistician and presented for iDMC review. Members of the iDMC', 'will be external to the Sponsor and will follow a charter that outlines their roles and', 'responsibilities.', 'A detailed description of the statistical methods that will be used for the primary analyses will', 'be provided in the Statistical Analysis Plan (SAP).', '6.5', 'EFFICACY ANALYSES', 'The efficacy analyses will involve evaluating the number of bleeds over time, the HRQoL of', 'patients, the health status of patients according to EQ-5D-5L scores, and assessing patient', 'preference for the emicizumab regimen compared with the previous regimen used.', 'The definition of a bleed is described in Section 4.5.7.1. Patients will be asked to record any', 'hemophilia medication use (including emicizumab) and information regarding any bleeding events.', 'The patients should record this information at least every week even if they do not', \"experience a bleed. The number of bleeds will be compared with patients' bleed rate prior to\", 'study entry and will be summarized descriptively.', 'HRQoL (using the Haem-A-QoL or the Haemo-QoL-SF), health status (using the EQ-5D-5L),', 'and patient treatment preference will be assessed as per the Schedule of Activities', '(Appendix 1', 'Schedule of Activities', 'Emicizumab - F. Hoffmann-La Roche Ltd', '144 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}